

Epstein–Barr virus AND Parvovirus B19

HLS - Year: 2025-2026

Dr. Sulaiman Mahmoud Bani Abdel-Rahman


MBBS, Mutah university

MSC Medical Microbiology – University of Manchester

PhD Medical Virology - University of Manchester




Epstein–Barr virus



EBV Structure

- Enveloped, double-stranded DNA virus
- Genome: Linear dsDNA
- Icosahedral nucleocapsid
- Four significant structural components:
 - Core containing viral DNA
 - Nucleocapsid
 - Tegument (protein layer between capsid and envelope)
 - Envelope with embedded glycoproteins



Clinical syndromes associated with EBV infection

- Infectious mononucleosis.
- Burkitt lymphoma.
- B-cell lymphomas
- Chronic EBV infection.
- Lymphoproliferative disorder in immunocompromised.
- Nasopharyngeal carcinoma.
- Hairy leukoplakia



EBV Epidemiology

- Ubiquitous worldwide distribution (>90% of adults seropositive)
- Primary infection typically occurs:
 - During childhood in developing countries (usually asymptomatic)
 - During adolescence or young adulthood in developed countries (~50% develop infectious mononucleosis)
- Lifelong persistence following primary infection



Transmission

- **Transmission:**


- Primarily through saliva ("kissing disease")
- Less commonly through blood transfusions, organ transplantation
- Possible vertical transmission (rare)



Viral life cycle


- **Cell entry:**

- EBV binds to receptors on the cell surface (**particularly CD21 on B cells**)
- Fusion with the cell membrane → nucleocapsid released into the cytoplasm
- Transported to the cell's nucleus → can enter lytic replication or latency



Viral replication cycle (cont.)

- **Lytic replication (or Productive replication):**
 - After latency or entry into nucleus → DNA becomes linear
 - Replication with viral DNA polymerase → assembly → bud out from the nuclear membrane
 - Outer envelope obtained from the cell membrane



Epithelial cells

B cell




Viral replication cycle

- **Latency:**

- After entry into nucleus → DNA becomes circular (episome)
- Only a portion of genes are expressed
- Can reactivate → lytic replication (trigger is unclear)
- Usually with b cells, but could occur on epithelial cells also.





Acute infectious mononucleosis

- **Presentation:**

- Fever
- Tonsillitis (swollen and erythematous tonsils that may be covered in exudate)
- Cervical lymphadenopathy (most commonly the posterior cervical and posterior auricular chains)
- Headache
- General malaise and fatigue
- Petechiae present at the junction between the hard and soft palates
- Hepatosplenomegaly
- Maculopapular rash (similar to measles, present in approximately 5% of cases)



Acute infectious mononucleosis



Exudative tonsillopharyngitis

Pharynx and tonsils in a patient with infectious mononucleosis. The tonsils are massively hypertrophied, touching at the midline (known as "kissing tonsils"), and covered with gray-white exudate. The visible parts of the pharynx are erythematous.



Infectious mononucleosis:

pharyngitis demonstrating exudative tonsillitis and an enlarged uvula in a 19-year-old undergraduate university student 5 days after onset of infectious mononucleosis





Lymphadenopathy in a patient with mononucleosis

Bilaterally enlarged cervical lymph nodes (black arrows) and submandibular lymph nodes are seen in the neck region of a patient with infectious mononucleosis.

Additionally, there is a pale, macular rash on the neck and upper chest. A rash seen in infectious mononucleosis may be caused by the infection itself but is more commonly due to antibiotic use.



Infectious mononucleosis

Etiology

Pathogen: Predominantly Epstein-Barr virus (EBV)
Transmission: mainly via saliva (hence the common name "kissing disease")

Epidemiology

Incidence (US): 5:1000 population/year
Peak age: 15–24 years
Prevalence (worldwide): > 90% adult population EBV-antibody positive

Clinical course

Incubation period: ~ 6 weeks
Symptoms usually last 2–4 weeks
Often asymptomatic in young children

Diagnosis


EBV serology, monospot test, CBC with differential

Treatment

Mainly symptomatic
Avoid strenuous physical activity for 3–4 weeks due to risk of splenic rupture

Complications

Upper airway obstruction
Splenic rupture
Wide range of rare complications in other organ systems (higher risk in immunocompromised individuals)



Acute infectious mononucleosis (cont.)

- **Management:**

- Supportive
- No available antiviral therapy



Oral hairy leukoplakia

- Oral hairy leukoplakia is caused by the reactivation of latent EBV and occurs mostly in patients who are HIV positive.
- **Clinical presentation:**
 - Not premalignant
 - White patches on the tongue
 - “Hairy” appearance (due to hyperkeratosis and epithelial hyperplasia)
 - Does not scrape off



White, hairy patch on a patient's tongue due to oral hairy leukoplakia



Oral hairy leukoplakia (cont.)

- **Management:**

- Treatment is not required.
- Antiretroviral therapy for HIV patients




EBV - diagnosis


- EBV is suspected when patients having
 - Fever
 - Pharyngitis
 - Lymphadenopathy
- CBC with differential
 - Absolute lymphocyte count $> 4 \times 10^9/L$
 - $> 50\%$ lymphocytes
 - $> 10\%$ **atypical lymphocytes**
- **Monospot (heterophile antibody) test:** a latex agglutination rapid test that uses red blood cells from horses to detect heterophile antibodies against EBV
- PCR (Most specific)



Reactive lymphocytes




Atypical CD8+ T lymphocyte



EBV – diagnosis (cont.)

- EBV serology is the most reliable laboratory study
- Antiviral capsid antigen antibodies (anti-VCA) for EBV
 - Anti-VCA IgM alone is sufficient to diagnose acute infection.
 - Anti-VCA IgG titers peak 2 weeks after symptom onset and may persist for life.
- EBV nuclear antigen (EBNA) antibodies are detectable ≥ 6 weeks after symptom onset and may persist for life.





Interpretation of VCA serology for EBV

	anti-VCA IgM	anti-VCA IgG	anti-EBNA IgG
Acute infection (0–6 weeks)	↑	↑ (titers peak at 2 weeks)	Undetectable
Past infection (≥ 6 weeks)	Undetectable	↑	↑



Parvovirus B19



Parvovirus B19 - Structure

- Human parvovirus B19 (the smallest of the DNA viruses infecting humans)
 - Family: Parvoviridae
 - Single-stranded DNA virus (linear)
 - Nonenveloped
- **Route of transmission**
 - Main route: aerosol
 - Other routes
 - Hematogenous transmission
 - Transplacental transmission: In seronegative pregnant women, transmission to the unborn fetus may occur (in up to 30% of cases).



Pathogenesis

- Parvovirus B19 binds to the P antigen (globoside) on **erythroid progenitor cells** → cellular invasion → viral DNA enters the nucleus of erythroid cells → viral DNA replication → cytotoxicity → clinical manifestations + transient cessation of erythropoiesis





Clinical Manifestations

Individuals may be asymptomatic or have any of the following presentations:

- 1. Erythema infectiosum (or fifth disease):**
In children, it produces rashes on the face with characteristic **slapped cheek appearance** (diffuse redness of the face with perioral sparing)

Adult women present with symmetrical polyarthropathy which usually involves the hand joints and knee



Clinical Manifestations

- 2. Transient aplastic crisis:** It can occur in infected patients with preexisting hematologic disease (eg, sickle cell anemia, hereditary spherocytosis), resulting in severe acute anemia
- 3. Non-immune hydrops fetalis** can occur in fetus, which results in fatal anemia and fetal death. Transplacental transmission occurs in 30% of cases and **maximum risk is in the second trimester**
- 4. Mild respiratory symptoms**
- 5. Parvovirus B19-associated arthritis**



Diagnosis

- Erythema infectiosum and parvovirus B19-associated arthritis are diagnosed clinically.
- Confirmatory studies for parvovirus B19
 - Immunocompetent individuals: IgM and IgG antibodies
 - IgM: usually detectable when the rash appears; remains positive for 2–3 months
 - IgG: positive after approx. 2 days; remains positive for life
 - Immunocompromised individuals: NAAT



TREATMENT

- No antiviral drug is available
- Symptomatic treatment is given
- Immunoglobulins containing neutralizing antibodies to human parvovirus are available commercially.





Thank You

